James Field, MD
Endocrinology, Diabetes & Metabolism · Martinsburg, WVNPI 1306134028
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Lilly USA, LLC at 28.4% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in WV, where the typical reported total is $1,166.
Across 50 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$264
- Abbott$221
- Amgen$112
- Insulet Corporation$105
- Novo Nordisk$58
- AstraZeneca$54
- plus $115 from 6 others
What the payments were for
- Food & beverage$90297%
- Education$283%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 16 | $264 |
| Abbott | 12 | $221 |
| Amgen | 2 | $112 |
| Insulet Corporation | 6 | $105 |
| Novo Nordisk | 4 | $58 |
| AstraZeneca | 3 | $54 |
| Boehringer Ingelheim | 2 | $28 |
| Bayer | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Radius Health, Inc. | 1 | $16 |
| GRT US Holding, Inc. | 1 | $15 |
How this compares
$930 in reported general payments places this provider in the 45th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 368 | $642,796 |
| MounjaroTirzepatide | 213 | $399,260 |
| TrulicityDulaglutide | 144 | $223,933 |
| JardianceEmpagliflozin | 123 | $196,280 |
| FarxigaDapagliflozin Propanediol | 146 | $142,947 |
| ForteoTeriparatide | 20 | $84,229 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 53 | $68,303 |
| Tresiba Flextouch U-100Insulin Degludec | 83 | $64,585 |
| RybelsusSemaglutide | 21 | $49,986 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 274 | $48,437 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 40 | $40,345 |
| Novolog FlexpenInsulin Aspart | 124 | $35,101 |
| JanuviaSitagliptin Phosphate | 16 | $27,012 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $20,679 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 41 | $19,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Baqsimi, Humalog | $264 | $723,775424 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $58 | $701,140406 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $28 | $219,013145 claims |
| AstraZenecaFarxiga | $54 | $142,947146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Martinsburg
- Zachary KistkaMartinsburg$120K
- Philip RyanMartinsburg$35K
- Sheila Ramirez RodriguezMartinsburg$5K
- Emma Morton-EgglestonMartinsburg$206
- Daniel MaciasHuntington$686K
- Jeremy SouleBridgeport$109K
- John EplingBridgeport$28K
- Greta GuyerSouth Charleston$22K
- Arlene FederWeirton$20K
- Ziad KahwashSouth Charleston$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.